Seamus Fernandez
Stock Analyst at Guggenheim
(4.83)
# 71
Out of 5,182 analysts
128
Total ratings
63%
Success rate
55.93%
Average return
Main Sectors:
Stocks Rated by Seamus Fernandez
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintains: Buy | $1,163 → $1,183 | $854.70 | +38.41% | 25 | Apr 22, 2026 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Buy | $72 | $58.21 | +23.69% | 15 | Apr 8, 2026 | |
| GENB Generate Biomedicines | Initiates: Buy | $30 | $12.32 | +143.51% | 1 | Mar 24, 2026 | |
| APGE Apogee Therapeutics | Maintains: Buy | $130 → $160 | $82.75 | +93.35% | 9 | Mar 24, 2026 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $25 → $30 | $15.76 | +90.36% | 3 | Mar 19, 2026 | |
| TENX Tenax Therapeutics | Maintains: Buy | $25 → $34 | $13.81 | +146.29% | 4 | Mar 16, 2026 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $34 → $35 | $22.58 | +55.04% | 4 | Feb 27, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $140 → $143 | $81.72 | +74.99% | 4 | Feb 27, 2026 | |
| SGMT Sagimet Biosciences | Initiates: Buy | $27 | $8.52 | +216.90% | 1 | Feb 3, 2026 | |
| PCVX Vaxcyte | Reiterates: Buy | $116 | $57.69 | +101.07% | 5 | Feb 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $140 | $41.47 | +237.59% | 3 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $77 → $88 | $28.68 | +206.83% | 5 | Jan 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $45.96 | - | 1 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $11 | $4.94 | +122.90% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.45 | - | 4 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $25.25 | - | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $130 → $122 | $110.55 | +10.36% | 14 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $51.83 | - | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.65 | - | 3 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $39.89 | - | 2 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $143.62 | - | 6 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.06 | - | 1 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $54 | $4.42 | +1,121.72% | 1 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $45 | $32.21 | +39.71% | 3 | Mar 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $36 → $38 | $186.20 | -79.59% | 6 | Feb 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $35 → $38 | $26.43 | +43.78% | 3 | Jan 31, 2018 |
Eli Lilly and Company
Apr 22, 2026
Maintains: Buy
Price Target: $1,163 → $1,183
Current: $854.70
Upside: +38.41%
Bristol-Myers Squibb Company
Apr 8, 2026
Reiterates: Buy
Price Target: $72
Current: $58.21
Upside: +23.69%
Generate Biomedicines
Mar 24, 2026
Initiates: Buy
Price Target: $30
Current: $12.32
Upside: +143.51%
Apogee Therapeutics
Mar 24, 2026
Maintains: Buy
Price Target: $130 → $160
Current: $82.75
Upside: +93.35%
Amylyx Pharmaceuticals
Mar 19, 2026
Maintains: Buy
Price Target: $25 → $30
Current: $15.76
Upside: +90.36%
Tenax Therapeutics
Mar 16, 2026
Maintains: Buy
Price Target: $25 → $34
Current: $13.81
Upside: +146.29%
Arcutis Biotherapeutics
Feb 27, 2026
Maintains: Buy
Price Target: $34 → $35
Current: $22.58
Upside: +55.04%
Rhythm Pharmaceuticals
Feb 27, 2026
Maintains: Buy
Price Target: $140 → $143
Current: $81.72
Upside: +74.99%
Sagimet Biosciences
Feb 3, 2026
Initiates: Buy
Price Target: $27
Current: $8.52
Upside: +216.90%
Vaxcyte
Feb 2, 2026
Reiterates: Buy
Price Target: $116
Current: $57.69
Upside: +101.07%
Jan 20, 2026
Maintains: Buy
Price Target: $90 → $140
Current: $41.47
Upside: +237.59%
Jan 16, 2026
Maintains: Buy
Price Target: $77 → $88
Current: $28.68
Upside: +206.83%
Dec 9, 2025
Downgrades: Neutral
Price Target: n/a
Current: $45.96
Upside: -
Nov 18, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $4.94
Upside: +122.90%
Oct 23, 2025
Downgrades: Neutral
Price Target: n/a
Current: $8.45
Upside: -
Feb 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $25.25
Upside: -
Jan 17, 2025
Maintains: Buy
Price Target: $130 → $122
Current: $110.55
Upside: +10.36%
Oct 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $51.83
Upside: -
Apr 29, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.65
Upside: -
May 31, 2022
Upgrades: Buy
Price Target: n/a
Current: $39.89
Upside: -
Feb 25, 2020
Downgrades: Neutral
Price Target: n/a
Current: $143.62
Upside: -
Feb 3, 2020
Downgrades: Neutral
Price Target: n/a
Current: $5.06
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $56 → $54
Current: $4.42
Upside: +1,121.72%
Mar 8, 2018
Maintains: Market Perform
Price Target: $60 → $45
Current: $32.21
Upside: +39.71%
Feb 6, 2018
Maintains: Market Perform
Price Target: $36 → $38
Current: $186.20
Upside: -79.59%
Jan 31, 2018
Maintains: Market Perform
Price Target: $35 → $38
Current: $26.43
Upside: +43.78%